Aquestive Therapeutics CEO Keith Kendall's 2021 pay jumps 59% to $2M
Aquestive Therapeutics reports 2021 executive compensation
By ExecPay News
Published: April 29, 2022
Aquestive Therapeutics reported fiscal year 2021 executive compensation information on April 29, 2022.
In 2021, three executives at Aquestive Therapeutics received on average a compensation package of $1.4M, a 24% increase compared to previous year.
Average pay of disclosed executives at Aquestive Therapeutics
Keith J. Kendall, Chief Executive Officer, received $2M in total, which increased by 59% compared to 2020. 50% of Kendall's compensation, or $1M, was in option awards. Kendall also received $450K in non-equity incentive plan, $550K in salary, as well as $32K in other compensation.
Daniel Barber, Chief Operating Officer, received a compensation package of $1.2M, which increased by 38% compared to previous year. 37% of the compensation package, or $424K, was in salary.
A. Ernest Toth, Jr, Chief Financial Officer, earned $1.1M in 2021.
Related executives
You may also like
Source: SEC filing on April 29, 2022.